Feb. 17, 2005 Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at the Free University of Brussels have recently published results that show promise in the quest for a new remedy for chronic urinary tract infections. The researchers have shown that administration of the sugar Heptyl-á-D-mannoside can prevent E. coli bacteria from binding to the wall of the urinary tract - which is the first step in the development of the infection.
A widespread problem
Urinary tract and bladder infections are among the most prevalent bacterial infections and can be quite painful. Fifty percent of all women are confronted by these unpleasant infections at some point in their lives. The disorder is an especially severe problem when it becomes chronic - whereby some patients experience symptoms almost continually. The Escherichia coli bacterium is responsible for 80% of these urinary tract infections. Treatment with antibiotics is possible but does not preclude a recurrence of the infection. In addition to this, more and more bacteria are becoming resistant to the antibiotics. For these reasons, scientists have been busy seeking another solution.
Prevention is better than cure
Julie Bouckaert and her co-researchers, under the direction of Henri De Greve, have discovered a way to prevent E. coli bacteria from adhering to the wall of the urinary tract, so that they can no longer cause infection. Because E. coli bacteria use very particular hair-like projections (called pili) to cling to tissues - the first stage of a potential inflammation - a drug that can prevent this attachment can also avert bladder and urinary tract inflammations.
Combating certain bonds
Bouckaert and De Greve have investigated the way in which the E. coli bacteria attach themselves. This attachment takes place by means of a reaction between the protein 'Adhesine FimH' on the tips of the pili and special receptors on the wall of the urinary tract. The researchers hypothesized that they could prevent this binding by administering a substance that would have a greater affinity with Adhesine FimH than with the receptors on the urinary tract. Then, the E. coli binding places would be so captivated by this particular substance that they would no longer be able to cling to the wall of the urinary tract.
Their search for such a substance proved fruitful. Via crystallography and affinity determinations, they demonstrated that the bacteria bind very strongly to the structure of the Heptyl-á-D-mannoside sugar. This binding is strong enough to prevent the bacteria from attaching themselves to the urinary tract wall. Therefore, administration of Heptyl-á-D-mannoside could prevent bladder infections. This finding opens possibilities for the development of a new medication for chronic urinary tract infections.
Other social bookmarking and sharing tools:
The above story is based on materials provided by Flanders Interuniversity Institute Of Biotechnology.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.